96 results about "Lymphatic/immune" patented technology

A composition for delivering a tumor therapeutic agent to a patient includes a fast-release formulation of a tumor apoptosis inducing agent, a slow-release formulation of a tumor therapeutic agent, and a pharmaceutically acceptable carrier. An apoptosis-inducing agent in a pharmaceutically acceptable carrier may be administered before or concomitantly therewith. Nanoparticles or microparticles (e.g., cross-linked gelatin) of the therapeutic agent (e.g., paclitaxel) also may be used. The nanoparticles or microparticles may be coated with a bioadhesive coating. Microspheres that agglomerate to block the entrance of the lymphatic ducts of the bladder to retard clearance of the microparticles through the lymphatic system also may be employed. This invention also uses drug-loaded gelatin and poly(lactide-co-glycolide) (PLGA) nanoparticles and microparticles to target drug delivery to tumors in the peritoneal cavity, bladder tissues, and kidneys.

The invention relates to a gadolinium-containing silicon dioxide nanosphere magnetic resonance contrast agent for lymphatic system specific imaging and a preparation method thereof. The contrast agent is nanosphere suspend liquid or powder formed by using water-soluble silicon dioxide to cover preparation containing gadolinium, wherein the particle size ranges from 50nm to 200nm; the weight ratio of the preparation containing gadolinium to the water-soluble silicon dioxide is between 1.86X10<-4> and 0.592. The nanosphere prepared by the invention has relatively high entrapment efficiency, can selectively enter Lymphatic capillaries but not capillary vessel, thereby being used for the lymphatic system specific imaging, reducing the interference of the capillary vessel, improving the sensitivity and specificity of the lymphatic qualitative diagnosis, as well as reducing the harm thereof to human body, therefore, the nanosphere magnetic resonance contrast agent is a new gadolinium-containing magnetic resonance contrast agent with high target.

The invention relates to a polysaccharide macromolecular paramagnetic metal complex and a synthesis method and an application thereof. Polysaccharide macromolecules are used as carriers, and a ligand compound, the side chains of which contain open-chain or annular polyamino polycarboxylic compounds, acts with paramagnetic metal ions to form the paramagnetic metal complex, wherein the paramagnetic metal ions are positive divalent or trivalent ions of metal elements, the atomic numbers of which are 21-29, 42 and 44 or 57-71. The polysaccharide macromolecular paramagnetic metal complex can be used as a magnetic resonance imaging contrast agent for lymphatic organs, lymphatic vessels, lymphatic systems and cardiovascular systems of people or other mammals.

The invention discloses an application of niclosamide or pharmaceutically-acceptable salts thereof in preparing anti-tumor drugs, which provides a candidate drug for tumor patients and may further improve the therapeutic effect and the prognosis to patients. The effectiveness of niclosamide or pharmaceutically-acceptable salts thereof on various tumor cells indicates that the composition may be used for treating various cancers such as cerebroma, genitourinary tumor, lymphatic system, stomach cancer, cancer of larynx, nasopharyngeal cancer, skin cancer, bone cancer, leukaemia, leukaemia, breast cancer, histiocytic lymphoma, non-small-cell lung cancer, small-cell lung cancer, lung adenocarcinoma, epidermoid cancer, pancreatic cancer, prostatic cancer, liver cancer and epithelial cell cancer.

The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.

The invention provides polynucleotides and genes that are differentially expressed in lymphatic versus blood vascular endothelial cells. These genes are useful targets for treating diseases involving lymphatic vessels, such as lymphedeman, various inflammatory diseases, and cancer metastasis via the lymphatic system.

An emulsified injection for treating cancers is prepared from brucea fruit oil, medical emulsifier, isotonic agent and water through respectively dissolving oil phase and water phase, emulsifying and homogenizing.

The present invention provides pharmaceutical compositions for topical delivery comprising a suitable carrier and a codrug capable of penetrating, or being transported across, the dermis. The codrug according to the invention comprises a first constituent moiety linked to a second constituent moiety, wherein the second constituent moiety is the same as, or different from, the first constituent moiety. The first and second constituent moieties are so linked that they are easily transported into or across the dermis, into the skin, or into the blood or lymphatic system, and are reconstituted in vivo to form the first and second constituent moieties.

Drainage of body fluid from a first area of the body to a target area of the body can be accomplished by interconnecting an artificial non-blood fluid conduit with the venous and/or lymphatic system of the body. For example, an artificial non-blood fluid conduit can be inserted into the eye to fluidly interconnect the anterior chamber with a venous structure, such as an anterior ciliary vein, or lymphatic in a target location of the eye. The outflow end of the conduit can be positioned adjacent to and/or cannulated within the venous structure or lymphatic. Further, the conduit can optionally have an angiogenic material for stimulating growth of new blood vessels in the target location to fluidly interconnect the venous structure or lymphatic with the anterior chamber using the non-blood fluid conduit.

The invention relates to a gadolinium-containing macromolecular contrast agent and a preparation method thereof. The structural formula of the contrast agent is shown as the specification and n is 16-185. The contrast agent can initiatively enter a lymph system and a tumor cell; and the contrast agent is initiatively absorbed by the lymph system and the tumor cell so that the sensitivity and the specificity of qualitative diagnosis of the lymph system and the tumor cell are improved.

A SARS virus antigen-antibody vaccine and its experimented method are disclosed. Said composite vaccine is prepared from the SARS virus antigen and specific antibody, and features that it can directly submit said virus antigen to the antigen presenting APC cells and mononuclear/macrophage for exciting the immune response mechanism of lymphatic immune system. Its advantages are high immune effect and specific target treatment to SARS.

The present invention relates to complexes which contain polycrystalline magnetic iron oxide particles in a pharmaceutically acceptable shell, and to the use of these compositions in magnetic particle imaging (MPI). Particular preference is given to the use of these compositions in examining the gastrointestinal tract, the vascular system of the heart and cranial components, in the diagnosis of arteriosclerosis, infarctions, and tumors and metastases, for example of the lymphatic system.

Devices and methods of treating fluid retention caused by congestive heart failure or other conditions resulting in edema, lymphoedema, or significant fluid retention (e.g., deep vein thrombosis, cellulitis, venous stasis insufficiency, or damage to the lymphatic network) are described. Specifically, a treatment device is used to create a passage or cannula between the lymphatic system (or other area of the body) and an external drainage device. This device can be only temporarily located in the patient or can be implanted within the patient for longer periods of time. The physician can safely and reliably remove excess fluid from the body via the device and optionally inject other treatment agents.

The invention discloses an elastic targeting polypeptide-based medicine-carrying nanoparticle. The nanoparticle is prepared from an elastic targeting polypeptide and a modified medicine, wherein the modified medicine is a modified paclitaxel PTX-LEV-MECH or modified salinomycin Sail-ABA-MPBH. The elastic targeting polypeptide-based medicine-carrying nanoparticle provided by the invention is 100nmor below in particle size, so that the dispersion degree is low, the medicine carrying rate is high, and the nanoparticle can be combined with in-vivo albumin for transferring and carrying medicine, and also can be combined with acidic rich cysteine specifically secreted by tumor cells, the drug is concentrated in the acidic environment, the breast cancer in-situ cancer is targeted for killing, and the toxic and side effects of the drug on the whole body are reduced; and the efficacy of treating breast cancer is increased and improved by utilizing the synergistic effect of two nanoparticles, the occurrence of the metastasis of the breast cancer cells through a lymphatic system and a blood system is reduced, and the occurrence of serious complications such as medical-source lymphatic edemacaused by a lymph node sweeping surgery is reduced.

The invention discloses a health-care food. The health-care food comprises the following ingredients in parts by weight: 60-65 parts of fructo-oligosaccharide, 10-20 parts of Arabic gum, 3-10 parts of oat fibers, 3-10 parts of pea fibers, 0.5-5 parts of guar gum, 0.5-1 part of cherry powder, 0.5-5 parts of citrus flavouring, 0.1-1 part of apple powder, 0.1-1 part of pectin, 1-5 parts of vegetable powder, 0.1-1 part of vitamin C, 0.1-1 part of complex plant enzyme, 0.1-1 part of inulin, 0.1-1 part of rice fibers, 0.01-0.1 part of catechin, 0.5-5 parts of beta-carotene, 0.01-0.1 part of lactobacillus, 0.01-0.1 part of vitamin E acetate, 0.01-0.1 part of turmeric and 0.01-0.1 part of selenium-enriched yeast. The health-care food has the function of repairing human cells, can enhance the self-healing and recovery instincts of human bodies and promote lymphatic system detoxification and cell and organ tissue repair, is resistant to oxidation and aging, improves the intestinal absorption and digestion functions, and has good health-care effects on the populations with sub-health and chronic diseases.

Provided herein is a method for determining cancer treatment using an immune modulating therapy in a subject in need thereof. The method comprises assessing whether a lymphatic system in a subject isdysregulated. When the lymphatic system is dysregulated, a treatment for the lymphatic system is determined before a therapeutic amount of an immune modulating therapy is administered to treat cancerin the subject. Alternatively, when the lymphatic system is dysregulated, an immune modulating therapy is selected to treat cancer in the subject, which immune modulating therapy is independent of immune-cell priming, antigen trafficking, antigen presentation, and any combination thereof. The subject may also be treated for cancer accordingly.

The invention discloses a health-care food. The health-care food comprises the following ingredients in parts by weight: 40-50 parts of fructo-oligosaccharide, 5-15 parts of calcium carbonate, 5-15 parts of magnesium carbonate, 0.5-5 parts of horsetail extracts, 1-5 parts of calcium lactate, 1-5 parts of potassium citrate, 0.1-1 part of zinc gluconate, 0.01-0.2 part of manganese gluconate, 0.01-0.1 part of copper gluconate, 0.1-1 part of beta-carotene, 0.01-0.1 part of chromium-chlorite, 0.005-0.01 part of sodium selenite and 0.005-0.1 part of vitamin D3. The health-care food has the function of repairing human cells, can enhance the self-healing and recovery instincts of human bodies and promote lymphatic system detoxification and cell and organ tissue repair, is resistant to oxidation and aging, has good health-care effects on the populations with sub-health and chronic diseases, and especially has an obvious renal function health-care effect.

The present invention relates to complexes which contain magnetic iron oxide particles in a pharmaceutically acceptable shell, said particles having a diameter of 20 nm to 1 [mu]m with an overall particle diameter/core diameter ratio of less than 6, and to the use of these complexes in magnetic particle imaging (MPI). Particular preference is given to the use of these compositions in examining the gastrointestinal tract, the vascular system of the heart and cranial components, in the diagnosis of arteriosclerosis, infarctions, and tumors and metastases, for example of the lymphatic system.

The invention discloses a head and neck lymph drainage regulation and control instrument and a use method thereof, and relates to the field of clinical neurology (neurosurgery and neurology). The head and neck lymph drainage regulation and control instrument comprises a drainage pump and a drainage head sleeve. The drainage head sleeve comprises a head beam, a locking knob, pressing earmuffs, an inflation bandage and an air pipe. An air bag structure is used for replacing human hands for massage, and the drainage speed of a lymphatic system to brain metabolites is increased by pressing lymphatic tissues in front of ears, behind ears and at the lower jaw, so that the purposes of reducing intracranial pressure and discharging toxic macromolecular proteins generated by metabolism of the brain tissues out of the cranium are achieved. When the physical method is used for massaging the head lymph of a patient, the discharge of intracranial harmful substances can be accelerated, the intracranial pressure of the patient can be reduced, the opportunity that the patient is subjected to surgical treatment can be reduced or avoided, the accumulation of intracranial harmful metabolites of the craniotomy patient can be reduced, the postoperative infection risk can be reduced or avoided, the discharge of head metabolic toxic macromolecular proteins can be accelerated, and the memory, sleep and neurocognition can be improved.